Abstract
BackgroundThere is a significant demand for the development of non-surgical methods for the evaluation of complete response to tumor therapy. Predicting ability and image quality of routine imaging has not been satisfactory. To avoid the deficiencies, we assessed the capability of three-dimensional transrectal ultrasound in predicting the response to neoadjuvant chemoradiotherapy in rectal cancer patients.MethodsThe inclusion criteria were patients with locally advanced rectal adenocarcinoma, receiving capecitabine-based neoadjuvant chemoradiotherapy, distance from anal verge (≤6 cm), clinical stage T3-4 and/or N+ without evidence of distant metastasis, and restaging ycT0-3a (T3a <5 mm) after the end of neoadjuvant chemoradiotherapy. Three-dimensional transrectal ultrasound was performed 7 weeks after neoadjuvant chemoradiotherapy to discern the patients with complete response from the others. Eight main parameters were obtained from three-dimensional transrectal ultrasound: thickness of muscularis on the residual side, thickness of contralateral muscularis, angle of residual arc, regularity of the shape, integrity of the mucosal layer, blurring of the margin, internal echo, and posterior echo. The association between tumor response and three-dimensional transrectal ultrasound parameters was analyzed, and a model was developed by logistic regression.ResultsBetween 2014 and 2019, 101 patients were recruited; 72 cases received total mesorectal excision, and 29 cases underwent watch-and-wait. Among the three-dimensional transrectal ultrasound parameters, the adjusted-thickness of the muscularis (P<0.01), angle of the residual arc (P<0.01), and regularity of the residual shape (P<0.01) were strongly associated with tumor response. In the dataset with total mesorectal excision cases (TME dataset), the residual adjusted-thickness (odds ratio [OR]=4.88, 95% confidence interval [CI]=1.44–16.6, P=0.01) and regularity of the residual shape (OR=5.00, 95% CI=1.13–22.2, P=0.03) were kept in the final logistic model. The area under the curve of the logistic model was 0.84. Among these parameters, residual adjusted-thickness correlated significantly with tumor response. Additionally, we observed similar results in the whole population of 101 cases (whole dataset) and in the cross-validation.ConclusionThree-dimensional transrectal ultrasound model is a valuable method for predicting tumor response in rectal cancer patients undergoing neoadjuvant chemoradiotherapy, which should be included as a factor for evaluating clinical complete response.Trial RegistrationThis trial was registered with ClinicalTrials.gov, number NCT02605265. Registered 9 November 2015 - Retrospectively registered, https://clinicaltrials.gov/ct2/show/record/NCT02605265
Highlights
For locally advanced rectal cancer (LARC) patients, neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision (TME) is the standard treatment [1]
After the completion of NACRT, patients were restaged by pelvic magnetic resonance imaging (MRI), and only patients judged as ycT0-3aN0 would take three-dimensional transrectal ultrasound (3D-TRUS). 3D-TRUS performed about 7 weeks after NACRT aimed to discern patients with complete response (CR) from those without
The current study demonstrates that the measurements of 3DTRUS at 7 weeks after completion of NACRT were significantly associated with tumor response in patients treated with curative intent for rectal cancer and reached ycT0-3aN0 evaluated by pelvic MRI
Summary
For locally advanced rectal cancer (LARC) patients, neoadjuvant chemoradiotherapy (NACRT) followed by total mesorectal excision (TME) is the standard treatment [1]. Endoscopic ultrasonography (EUS) showed a potential predictive ability to detect tumor regression grade 3–4 (TRG 3–4, >10% vital tumor cells) residual disease, 12 weeks after completion of NACRT with a sensitivity of almost 90% in esophageal cancer. It could detect cases without vital tumor cells with the sensitivity of >50% [4]. A similar study compared 3D-TRUS and EUS for rectal cancer staging and found 91% accuracy of 3D-TRUS for pT2 and 85% for pT3. We assessed the capability of three-dimensional transrectal ultrasound in predicting the response to neoadjuvant chemoradiotherapy in rectal cancer patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
